Cervical cancer is the leading cause of cancer-related death of women in developing countries including China. Virtually all cases of cervical cancer are caused by specific types of human papillomavirus (HPV) . Vaccination of high-risk HPV types is ultimate solution to increase protection against virus infection and consequently reduce risk of Cervical cancer.
Gproan is engaged in developing multivalent VLPs HPV vaccine that specifically target the HPV types affecting Chinese population. Our 6-valent HPV vaccine is under pre-clinical study of animal testing and is expected to be approved by China Food and Drug Administration (CFDA) soon.
